Effects of ATF2/TSC1 on epilepsy by modulating the microphages polarization of microglia

Wenjiao Huang1,2, Wenli Chen3, Zhong Zhao3

  • 1School of Medicine, Kunming University of Science and Technology, No. 727 Jingming South Road, Kunming, 650500, Yunnan, China. drhuangwenjiao@126.com.

Scientific Reports
|July 2, 2025
PubMed

Insights

Activating transcription factor 2 (ATF2) drives neuroinflammation in epilepsy by promoting microglial M1 polarization and suppressing TSC1. Inhibiting ATF2 and boosting TSC1 may offer new epilepsy treatment strategies.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Epilepsy (EP) is a chronic neurological disorder with complex causes.
  • Microglia-mediated inflammatory responses are key contributors to EP progression.
  • The role of Activating Transcription Factor 2 (ATF2) in EP-related neuroinflammation is not well understood.

Purpose of the Study:

  • To investigate the role of ATF2 in kainic acid (KA)-induced epilepsy.
  • To explore the relationship between ATF2, microglial polarization, and neuroinflammation in EP.
  • To determine the interaction between ATF2 and TSC1 in the context of EP.

Main Methods:

  • Established EP cell and mouse models using kainic acid (KA).
  • Quantified gene and protein expression (ATF2, TNF-α, IL-6, TSC1) via PCR and Western blot.
  • Assessed microglial polarization using immunofluorescence and flow cytometry; verified ATF2-TSC1 interaction with dual-luciferase and ChIP assays.

Main Results:

  • KA induced M1 microglial polarization and increased pro-inflammatory cytokines (TNF-α, IL-6) in HMC3 cells.
  • ATF2 expression was upregulated, while TSC1 was downregulated in KA-induced EP models.
  • ATF2 knockdown reduced M1 polarization and neuroinflammation, whereas TSC1 overexpression inhibited M1 polarization; ATF2 negatively regulated TSC1 transcription.

Conclusions:

  • ATF2 promotes M1 microglial polarization and neuroinflammation in experimental epilepsy.
  • ATF2 directly binds to and suppresses the promoter of TSC1.
  • Inhibiting ATF2 and promoting TSC1 transcription represent potential therapeutic strategies for EP neuroinflammation.